Advanced Search

Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Grade Last Price % Change Price Change
D 2.08 5.58% 0.11
CANF closed up 5.58 percent on Friday, May 14, 2021, on 3 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
8 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical CANF trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 5.58%
Outside Day Range Expansion 5.58%
Oversold Stochastic Weakness 5.58%
200 DMA Resistance Bearish 4.00%
Lower Bollinger Band Walk Weakness 4.00%
Oversold Stochastic Weakness 4.00%
Older End-of-Day Signals for CANF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 3 days ago
Up 5% 3 days ago
200 DMA Resistance 3 days ago
10 DMA Resistance 3 days ago
Rose Above 10 DMA 3 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Immunology Treatment Of Cancer Inflammatory Disease Inflammatory Diseases Rheumatoid Arthritis Carcinoma Psoriasis Glaucoma Arthritis Hepatocellular Carcinoma Immunosuppressants Petach Uveitis Biotie Therapies Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Treatment Of Psoriasis Immune Inflammatory Diseases

Is CANF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
May 12 CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES
May 6 Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
Apr 29 Can-Fite’s reaches 75% enrollment in late-stage psoriasis study; Top line results expected in Q4
Apr 29 Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
Apr 22 Can-Fite Expands Mid-Stage COVID-19 Study To Europe
Apr 22 Can-Fite Expands its Phase II COVID-19 Study to Europe
Apr 20 Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
Apr 20 Can-Fite initiates preclinical studies of its two lead drug candidates
Apr 20 Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
Apr 19 GME, CLNE, WPRT and CLOV among notable premarket gainers
See more CANF news...

Indicators

Indicator Value
52 Week High 4.38
52 Week Low 1.51
Average Volume 4,096,978
200-Day Moving Average 2.04
50-Day Moving Average 2.24
20-Day Moving Average 2.12
10-Day Moving Average 2.05
Average True Range 0.12
ADX 14.8
+DI 18.70
-DI 17.61
Chandelier Exit (Long, 3 ATRs ) 1.96
Chandelier Exit (Short, 3 ATRs ) 2.30
Upper Bollinger Band 2.31
Lower Bollinger Band 1.93
Percent B (%b) 0.39
BandWidth 17.92
MACD Line -0.07
MACD Signal Line -0.06
MACD Histogram -0.0072
Fundamentals Value
Market Cap 32.06 Million
Num Shares 15.4 Million
EPS -5.01
Price-to-Earnings (P/E) Ratio -0.42
Price-to-Sales 21.45
Price-to-Book 3.07
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.25
Resistance 3 (R3) 2.23 2.15 2.22
Resistance 2 (R2) 2.15 2.11 2.16 2.21
Resistance 1 (R1) 2.12 2.09 2.14 2.14 2.20
Pivot Point 2.04 2.04 2.05 2.05 2.04
Support 1 (S1) 2.01 2.00 2.03 2.03 1.96
Support 2 (S2) 1.93 1.98 1.94 1.95
Support 3 (S3) 1.90 1.93 1.94
Support 4 (S4) 1.92